RT Journal Article
SR Electronic
T1 Humoral immune responses against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.29.21268529
DO 10.1101/2021.12.29.21268529
A1 Kapil K. Saharia
A1 Jennifer S. Husson
A1 Silke V. Niederhaus
A1 Thierry Iraguha
A1 Stephanie V. Avila
A1 Youngchae J. Yoo
A1 Nancy M. Hardy
A1 Xiaoxuan Fan
A1 Destiny Omili
A1 Alice Crane
A1 Amber Carrier
A1 Wen Y. Xie
A1 Erica Vander Mause
A1 Kim Hankey
A1 Sheri Bauman
A1 Patricia Lesho
A1 Heather D. Mannuel
A1 Ashish Ahuja
A1 Minu Mathew
A1 James Avruch
A1 John Baddley
A1 Olga Goloubeva
A1 Kirti Shetty
A1 Saurabh Dahiya
A1 Aaron P. Rapoport
A1 Tim Luetkens
A1 Djordje Atanackovic
YR 2022
UL http://medrxiv.org/content/early/2022/01/01/2021.12.29.21268529.abstract
AB Background Solid organ transplant recipients (SOTR), who typically receive post-transplant immunosuppression, show increased COVID-19-related mortality. It is unclear whether an additional dose of COVID-19 vaccines in SOTR can overcome the reduced immune responsiveness against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants.Methods We performed a prospective cohort study of 53 SOTR receiving SARS-CoV-2 vaccination into a prospective cohort study performing detailed immunoprofiling of humoral immune responses against SARS-CoV-2 and its variants.Results Prior to the additional vaccine dose, 60.3% of SOTR showed no measurable neutralization and only 18.9% demonstrated neutralizing activity of >90% following two vaccine doses. More intensive immunosuppression, antimetabolites in particular, negatively impacted antiviral immunity. While absolute IgG levels were lower in SOTR than controls, antibody titers against microbial recall antigens were in fact higher. In contrast, SOTR showed reduced vaccine-induced IgG/IgA antibody titers against SARS-CoV-2 and its delta variants. Vaccinated SOTR showed a markedly fewer linear B cell epitopes, indicating reduced B cell diversity. Importantly, a third vaccine dose led to an increase in anti-SARS-CoV-2 antibody titers and neutralizing activity across alpha, beta and delta variants. However, we observed a significant decrease in anti-spike antibody titers with the omicron variant.Conclusions Only a small subgroup of SOTR generated functionally relevant antibodies after completing the initial vaccine series based on dysfunctional priming of immune responses against novel antigens. An additional dose of the vaccine results in dramatically improved antibody responses against all SARS-CoV-2 variants except omicron.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by two grants from the Kahlert Foundation. In addition, the study was supported in part by funds from the Division of Infectious Diseases and the Transplantation Program of the University of Maryland.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of the University of Maryland gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.